CLL Coverage from Every Angle
Advertisement
Advertisement

Recent News

Time-Limited Venetoclax-Based Combination Therapies for CLL
In Memoriam: Remembering Hematologist Steve E. Coutre, MD
Updated Phase I/II BRUIN Study of Next-Generation BTK Inhibitor Pirtobrutinib in CLL
SEQUOIA Update on Zanubrutinib Versus Bendamustine Plus Rituximab in CLL
Preclinical Findings With Novel CDK9 Inhibitor in CLL
ASH 2021: Update From ASCEND Trial of Acalabrutinib Monotherapy for Resistant CLL
ASH 2021: Updated Phase III FLAIR Results of Ibrutinib Plus Rituximab in Previously Untreated CLL
ASH 2021: Early Results With Zanubrutinib Plus Venetoclax in High-Risk CLL
ASH 2021: Combination Umbralisib and Ublituximab With Ibrutinib in CLL
Immunodeficiency and CLL Associated With IKZF3 Mutation: Focus on One Family
All in the Family: Shared Immunogenetic Characteristics in Familial CLL
Predicting Richter Transformation in Patients With Advanced-Stage CLL
Combination Obinutuzumab Treatment and MRD Kinetics in CLL: Insights From CLL14 Study
Ibrutinib Discontinuation and Risk of Disease Progression: Two Case Studies
Orphan Drug Designation Given to Bispecific Antibody CLL Treatment
Venetoclax and Quality of Life of Patients With Relapsed or Refractory CLL
Mechanistic Insight on Antiapoptotic Multidrug-Resistant Phenotype of CLL
CLL and COVID-19: Clinical and Immunologic Responses Under Study in Sweden
Ibrutinib-Treated Patients With CLL: Clarifying the Risk of Cardiovascular Events
Is Ibrutinib of Benefit for High-Risk, Treatment-Naive Patients With CLL?
What to Consider When Selecting Targeted Agents for CLL
Minimal Residual Disease Testing in CLL: Is It Ready for Prime Time?
Antibody Response in Patients With CLL Following COVID-19 Vaccination
CLL–International Prognostic Index in Predicting Cause of Death in Newly Diagnosed CLL
Predicting Response to COVID-19 Vaccine in Patients With CLL
Emerging Targeted Therapies Under Study in CLL
SOHO 2021: How Does Acalabrutinib Measure Up Against Ibrutinib in CLL?
SOHO 2021: Early-Phase Results With Novel BTK Inhibitor in CLL
SOHO 2021: Understanding Clinical Outcomes in Patients With CLL Older Than 80
SOHO 2021: Case-Based Look at First-Line Therapy for Younger Patients With CLL
SOHO 2021: Can the Natural History of Immune Dysfunction and Infections in CLL Be Altered?
COVID-19 in Patients With CLL: Is Neutropenia a Risk Factor?
Predicting Survival in Patients With CLL: Focus on TP53 Mutations
Statin Use in Patients With CLL: Impact on Survival Outcomes
Can the NOTCH Network Be Used to Refine Risk Stratification in CLL?
Karyotypic Complexity and Evolution May Impact Survival of Ibrutinib-Treated Patients With CLL
Managing CLL During the COVID-19 Pandemic: An Italian Report
Incidence of Neutropenia With Venetoclax and Obinutuzumab in CLL
How Does Acalabrutinib Measure Up Against Ibrutinib in CLL in Phase III Trial?
Case Study: Autoimmune Hemolytic Anemia in Male Patient With CLL
Ibrutinib Plus Venetoclax in CLL: Oral Nonchemotherapy Regimen Under Study
Cohort Study of CLL and Leukemia Cutis From the French Innovative Leukemia Organization


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.